AXIONOVA^™ compounds, biological systems, protocol structures, stack logic, AXIS, the AXIONOVA^™ Ring and Bracelet, AXIONOVA^™ bio, ALETHA^™ AI support, ALETHRA^™ governance records, catalog content, certificates, lot records, chain-of-custody documentation, practitioner-support materials, reseller-support materials, access-gate acknowledgements, and related communications.

1. Core Compounding and Prescription Statement

AXIONOVA^™ is a precision health technology platform organized around 30 compound identities across 10 biological systems, governed access, practitioner review, compound identity records, chain-of-custody controls, device-event context, physiology trends, and AI-assisted support. AXIONOVA^™ is a technology platform; it is not a pharmacy and not a medical practice. Compounded formulations referenced through AXIONOVA^™ compounds, compound documentation, protocol structures, stack descriptions, biological-system logic, and related formulary materials are prescribed by licensed physicians and dispensed by licensed compounding pharmacies.

AXIONOVA^™ Compounding Boundary: AXIONOVA^™ compounds and compound-related materials are personalized medications prepared by licensed compounding pharmacies pursuant to valid prescriptions issued by licensed healthcare providers for individually identified patients. Compounded medications are not FDA-approved. The FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed. Compounded medications are prepared based on a prescriber's determination that no commercially available FDA-approved product meets the patient's specific medical needs. All clinical decisions, including the determination of medical necessity, dosing, and monitoring, are made exclusively by the prescribing physician.

Compounded medications are prepared under the federal and state laws that govern pharmacy compounding by licensed pharmacies. AXIONOVA^™ does not represent any compounded formulation as an FDA-approved drug or as a COFEPRIS-authorized medicine for general therapeutic marketing. Final regulatory classification of any material must be confirmed by qualified regulatory counsel and applicable authorities.

2. No FDA Approval, No COFEPRIS Authorization for Therapeutic Use Unless Expressly Stated

AXIONOVA^™ materials should not be interpreted as evidence that any compound, stack, protocol, device, AI output, wellness trend, or practitioner-support material has been reviewed, cleared, approved, registered, or authorized by the U.S. Food and Drug Administration (FDA), Mexico’s Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), or any other health authority for treatment, diagnosis, cure, mitigation, prevention, human consumption, human injection, disease management, or public therapeutic marketing.

COFEPRIS is Mexico’s sanitary-risk authority for health inputs, health establishments, sanitary permits, sanitary registrations, licenses, import, and related proceedings. Any use, import, export, distribution, research, storage, handling, labeling, advertising, or professional activity involving AXIONOVA^™ materials in Mexico must be evaluated under applicable COFEPRIS, Ley General de Salud, Reglamento de Insumos para la Salud, consumer-protection, customs, and professional requirements.

3. No Medical Advice, Diagnosis, Treatment, or Emergency Service

AXIONOVA^™ website content, access-gate materials, catalog entries, biological-system descriptions, compound summaries, certificate references, protocol windows, stack structures, AXIONOVA^™ Ring and Bracelet trends, AXIS events, AXIONOVA^™ bio records, ALETHA^™ outputs, ALETHRA^™ audit records, practitioner-support materials, and reseller-support materials are for informational, research, governance, education, compliance, and recordkeeping purposes only.

AXIONOVA^™ does not provide medical advice, diagnosis, treatment, prescription, dispensing instruction, emergency care, or individualized therapeutic direction through public materials or AI-assisted outputs. Any individual experiencing symptoms, adverse events, or a potential emergency should contact emergency services or a licensed medical professional immediately.

AXIONOVA^™ AGIS Monitoring and Validation Boundary

AXIONOVA^™ AGIS public materials may describe dual-device verification, preventative monitoring, baseline-aware optimization, signal-confidence review, provenance, consent controls, and approved workflow boundaries. AXIONOVA^™ AGIS materials must not describe AXIONOVA^™ AGIS as a standalone emergency system, diagnostic system, automated medical decision-maker, or substitute for emergency services. Safety Escalation Workflow may be referenced only as an exclusive AXIONOVA^™ AGIS capability available through approved configuration, validation, jurisdictional review, and governed access.

4. Practitioner and Research-Entity Responsibility

AXIONOVA^™ access is governed through two paths. Path 1 is for licensed practitioners and qualified organizations that submit credentials and documentation. Path 2 is for trainers, spas, coaches, and individuals who require AXIONOVA^™’s on-staff doctors for telehealth oversight. Both paths remain subject to prescription requirements, consent requirements, documentation, privacy review, jurisdictional availability, and human oversight. These parties remain independently responsible for evaluating whether any activity involving AXIONOVA^™ materials is lawful, ethical, properly approved, properly supervised, appropriately documented, and consistent with their own professional duties.

Professional Responsibility Area

Boundary

Licensure and scope of practice

Practitioners must maintain active licensure and act only within authorized scope.

Research approval and oversight

Research entities must obtain institutional, ethical, biosafety, participant-consent, and other approvals when required.

Informed consent and authorization

Clinics and practitioners must obtain legally sufficient consents and authorizations before collecting or submitting personal, biometric, physiological, laboratory, or health-related data.

Chain of custody

Professional users must preserve identity, lot, certificate, storage, handling, transfer, and disposition records where applicable.

Advertising and claims

Professional users and resellers must not make unsupported health, safety, efficacy, disease, before-and-after, endorsement, or approval claims.

Jurisdictional compliance

Users must comply with U.S., Mexico, state, local, import/export, COFEPRIS, FDA, FTC, consumer-protection, privacy, and professional requirements.

AXIONOVA^™’s provision of information, access review, certificates, AI support, or governance tools does not replace the user’s duty to obtain independent legal, regulatory, clinical, scientific, and ethics review.

5. Governed Access Gate and Eligibility

AXIONOVA^™ uses a governed access gate to confirm basic eligibility and acknowledgements before restricted materials are released. Access-gate acceptance does not guarantee approval, product availability, purchase rights, regulatory authorization, clinical eligibility, reseller authorization, import/export permission, or permission to use materials outside prescription and physician-authorization boundaries.

AXIONOVA^™ may monitor and log access-gate activity, restricted catalog access, Datasite room access, DocuSign attestations, AXIONOVA^™ bio access, ALETHRA^™ governance records, AXIS events, AXIONOVA^™ Ring and Bracelet integrations, and partner portal activity. AXIONOVA^™ may deny, revoke, suspend, or condition access where it identifies suspected misuse, diversion risk, unsupported claims, security concerns, credential issues, jurisdictional restrictions, or inconsistent intended use.

6. ALETHRA^™ Governance Is Not Proof of Therapeutic Effect

ALETHRA^™ is AXIONOVA^™’s governance layer for identity, verification, authorization, chain-of-custody, access controls, compliance records, cartridge records, device-event logs, and provenance. ALETHRA^™certification or verification may support identity review, lot traceability, document control, access authorization, audit readiness, and record integrity.

ALETHRA^™ certification does not mean that a compound is FDA-approved, COFEPRIS-authorized for therapeutic use, clinically proven for a disease claim, safe for human use, effective for any outcome, or appropriate for a particular person. A verified source record is not a clinical conclusion.

7. ALETHA^™ AI Is Supportive, Not Determinative

ALETHA^™ is AXIONOVA^™’s AI operator for guided education, protocol-context explanation, progress summaries, user support, and practitioner-review preparation. ALETHA^™ may process source data, AXIS events, AXIONOVA^™ Ring and Bracelet trends, laboratory data, symptoms, adherence, nutrition, notes, and practitioner inputs to generate summaries, explanations, preparatory questions, or review flags.

ALETHA^™ outputs are not medical advice, not diagnoses, not prescriptions, not emergency instructions, not proof of compound effect, not regulatory determinations, and not substitutes for licensed practitioner judgment. AI outputs may be incomplete, inaccurate, biased, stale, or unsuitable for a specific user, population, research design, jurisdiction, or professional standard. Protocol-dependent decisions must be routed through authorized professional review.

8. AXIONOVA^™ bio: Data Levels and Interpretation Boundaries

AXIONOVA^™ bio is designed to distinguish source data, derived wellness features, protocol context, and review logic. AXIONOVA^™’s public materials emphasize that a PPG waveform is not HRV by itself, HRV is not a diagnosis, a BioZ trend is not a body-composition replacement, and a protocol window is not proof of compound effect.

Data Level

Examples

Interpretation Boundary

Source data

AXIS event, cartridge identity, PPG waveform, temperature, IMU motion, EDA, BioZ, lab result, symptom log, nutrition entry, practitioner note.

Source context only; requires quality review, provenance, and appropriate interpretation.

Derived wellness features

HRV trend, sleep context, recovery readiness, stress-load proxy, hydration trend, activity strain, temperature deviation.

Baseline-aware wellness trend; not a diagnosis or treatment directive.

Protocol context

Compound record, timing, adherence, AXIS event, user-reported outcome, practitioner annotation.

Protocol documentation and review support; not proof of safety, efficacy, or causation.

Review logic

Low-confidence window, repeated strain, symptom cluster, practitioner-review flag, validation-roadmap label.

Support for review; not automated care or clinical determination.

Users must not remove or contradict AXIONOVA^™ boundary labels, confidence labels, specialized-use labels, validation-roadmap labels, or practitioner-review requirements.

9. AXIS and AXIONOVA^™ Ring and Bracelet Boundaries

AXIS is described as a governed delivery instrument that preserves manual user action while recording identity, lock-state confirmation, authorization, protocol-compliance context, and event traceability. The AXIONOVA^™ Ring and Bracelet are described as a dual wearable physiology system that streams trends such as heart rate, HRV, sleep context, temperature deviation, activity context, SpO₂ wellness-trend support, EDA, and BioZ context into AXIONOVA^™ bio.

AXIS and AXIONOVA^™ Ring and Bracelet outputs must be interpreted according to validated use, applicable labeling, signal quality, user context, and jurisdictional regulatory status. Unless expressly authorized in writing, AXIS, the AXIONOVA^™ Ring and Bracelet, and related outputs are not represented as devices or outputs approved to diagnose, treat, cure, mitigate, or prevent disease. AXIS event records do not prove correct use, safety, efficacy, sterility, suitability, or therapeutic outcome.

10. Protocols, Stacks, and Biological Systems

AXIONOVA^™ protocol structures, stack logic, and biological-system classifications are designed to organize protocol objectives, pathway context, timing, monitoring requirements, companion-compound logic, and documentation workflows. A stack is a protocol structure, not a consumer product bundle, prescription, dosing instruction, or guaranteed outcome.

Any descriptions of weight loss, repair, recovery, regenerative, longevity, performance, cognitive, hormonal, metabolic, immune, or other biological systems are scientific-context descriptions provided for physician review. They must not be converted into consumer therapeutic claims, disease claims, guaranteed benefit claims, or self-directed use instructions unless supported by applicable regulatory authorization and written AXIONOVA^™approval.

11. Advertising, Marketing, and Public Statements

All advertising, promotional, educational, reseller, practitioner, conference, social media, email, website, and investor-facing statements about AXIONOVA^™ must be truthful, non-misleading, appropriately substantiated, and consistent with AXIONOVA^™-approved materials. FTC health-products guidance requires health-related claims to be truthful, not misleading, and supported by adequate substantiation, generally competent and reliable scientific evidence.

Mexico’s Federal Consumer Protection Law requires information and advertising to be truthful, verifiable, clear, and free from misleading or abusive content, and imposes specific obligations for electronic transactions, including confidentiality, security, truthful product characteristics, clear terms, and honoring consumer advertising preferences.

No AXIONOVA^™ user, reseller, practitioner, clinic, research entity, partner, employee, contractor, or affiliate may make unauthorized statements that AXIONOVA^™ materials are FDA-approved, COFEPRIS-authorized for therapeutic use, clinically proven for disease treatment, safe for unsupervised human use, guaranteed to produce results, endorsed by AXIONOVA^™ for consumer therapeutic use, or suitable for a particular person.

12. No Reliance on Public Website Content

AXIONOVA^™ public website content is intended to describe AXIONOVA^™’s platform, access model, governance architecture, formulary taxonomy, technology roadmap, and professional workflows. Public content may be updated, incomplete, delayed, aspirational, jurisdiction-limited, or subject to regulatory validation. It should not be relied upon as final labeling, final regulatory classification, professional instructions, clinical protocol approval, import/export authorization, investment advice, medical advice, or legal advice.

Restricted materials may be subject to separate agreements, non-disclosure obligations, data-room controls, DocuSign acknowledgements, jurisdictional limits, reseller restrictions, and professional review requirements.

13. International and Mexico-Specific Notice

AXIONOVA^™’s international access currently includes U.S. and Mexico-oriented workflows, with other jurisdictions potentially added later. Users outside the United States must not assume that a U.S.-oriented compounding and prescription statement permits possession, import, export, research, distribution, advertising, professional use, patient use, or resale in their jurisdiction.

In Mexico, activities involving health inputs, research materials, importation, sanitary control, advertising, professional conduct, and electronic commerce may be regulated by COFEPRIS, Ley General de Salud, Reglamento de Insumos para la Salud, Ley Federal de Protección al Consumidor, LFPDPPP, customs rules, tax rules, and professional requirements. Mexico-facing materials may require Spanish labeling, Spanish notices, local responsible-party information, transfer disclosures, and legally compliant privacy notices.

14. Adverse Events, Safety Signals, and Reporting

AXIONOVA^™ does not invite or authorize use of compounded medications without a valid prescription. If AXIONOVA^™ receives information suggesting an adverse event, misuse, diversion, use without a valid prescription, improper claim, product quality concern, device issue, privacy incident, security incident, or regulatory concern, AXIONOVA^™ may preserve records, suspend access, request documentation, notify appropriate parties, and take corrective or preventive action as required or appropriate.

Users, practitioners, clinics, resellers, and research entities must promptly report suspected misuse, diversion, product-quality issues, device anomalies, labeling concerns, unauthorized claims, access breaches, and safety signals to AXIONOVA^™ at safety@axionova.com or legal@axionova.com. Reporting a concern to AXIONOVA^™ does not replace any legally required report to regulators, institutional review boards, ethics committees, professional boards, emergency services, or other authorities.

15. Required Placement and Repetition of Disclaimer

AXIONOVA^™ should place a concise version of this disclaimer in high-risk contexts, including the access gate, catalog pages, compound pages, protocol pages, stack pages, AXIS and AXIONOVA^™ Ring and Bracelet pages, AXIONOVA^™ bio onboarding, ALETHA^™ sessions, DocuSign acknowledgements, Datasite rooms, reseller documents, clinic onboarding, certificates, lot records, labels, inserts, marketing approvals, and email communications.

A short-form disclaimer may read:

Prescription required. Compounded medications are prepared for individual patient use pursuant to a valid prescription from a licensed practitioner. Compounded medications are not FDA-approved. All clinical decisions, including dosing, are made by your licensed physician. AXIONOVA^™ does not practice medicine. ALETHA^™ AI outputs and AXIONOVA^™bio trends support governed review only and do not replace licensed professional judgment.

16. Contact

Questions regarding this Compounding & Platform Disclaimer, suspected misuse, unsupported claims, jurisdictional restrictions, product-quality issues, AI-output concerns, safety signals, or regulatory issues may be sent to:

AXIONOVA^™ Compliance / LegalAXIONOVA^™ INC.
Email: legal@axionova.com
Safety: safety@axionova.com

AXIONOVA™ Compounding & Platform Disclaimer